Early Cancer Detection: Toward Risk-Stratified, Multi-Modal Screening Paradigms
This Nature Medicine review maps the future of early cancer detection, arguing that progress hinges on individualized risk assessment, precise delineation of pre-malignant stages, and testing methods that distinguish indolent from lethal lesions. The authors highlight emerging sensor technologies, molecular assays, contrast agents, and AI-driven signal interpretation as key enablers. They stress that risk-based detection must be cost-effective and broadly accessible to meaningfully reduce the societal cancer burden.
The original study
The future of early cancer detection.
- Authors
- Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N
- Journal
- Nature medicine
- Type
- Journal Article, Review
- PMID
- 35440720
Original abstract
A proactive approach to detecting cancer at an early stage can make treatments more effective, with fewer side effects and improved long-term survival. However, as detection methods become increasingly sensitive, it can be difficult to distinguish inconsequential changes from lesions that will lead to life-threatening cancer. Progress relies on a detailed understanding of individualized risk, clear delineation of cancer development stages, a range of testing methods with optimal performance characteristics, and robust evaluation of the implications for individuals and society. In the future, advances in sensors, contrast agents, molecular methods, and artificial intelligence will help detect cancer-specific signals in real time. To reduce the burden of cancer on society, risk-based detection and prevention needs to be cost effective and widely accessible.